Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cartesian Therapeutics, Inc. (RNAC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.82+6.40%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RNAC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Release topline data from Phase 3 AURORA trial in Q1 2027 | The company plans to share key trial data in early 2027. | Intact | Data release delayed past Q1 2027 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
RNAC is a speculative, clinical-stage biotechnology business, with its long-term thesis tied to progress in its trials. The thesis is currently intact, though its signal has shifted from mildly favorable to mixed and the evidence confidence is medium.
RNAC is valued at a premium to peers, with low model confidence and a meaningful expectations gap driven by the possibility of future value from its pipeline. The evidence labels the pricing unjustified, but says valuation is the only part of a broader risk stack that is elevated, so the pricing fragility rating is low.
Near term, recent financial performance is neutral and earnings are loss-making; an earnings beat was reported in August, but recent earnings surprises have been erratic. Management is progressing the AURORA, TRITON, and HELIOS trials, with key data expected in the first half of 2027, while the AURORA topline result is expected in Q1 2027 and a filing is planned by mid-2027.
The multi-year thesis hinges on trial progress and whether upcoming data support the planned regulatory filing. Near-term risks include a guidance cut and weakening jobs data, while continued strong results and higher guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, RNAC remains a high-risk, loss-making clinical-stage story with an intact but mixed thesis. Trial evidence and delivery against timelines matter more than the recent earnings beat. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Cartesian aims to finish its Phase 3 trial by mid-2027. |
| Intact |
| Trial completion delayed beyond mid-2027 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08, Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 patients with acetylcholine receptor autoantibody positive (AChR Ab+) MG.” “• Research and development expenses were $20.4 million for the three months ended June 30, 2026, compared to $14.9 million for the three months ended June 30, 2025.” Delivery assessment Nov 4, 2026 |
Execute announced share buyback program | It has started a share buyback program. | Improving | No buyback activity by end 2026 | Buyback announced May 2026 vs target by end 2026 May 2026 8-K filing confirms entry into a Loan and Security Agreement and announcement of a share buyback program. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.83 → $-4.16 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.83 | $458,857 | 4 / 6 |
| 2026-07-25 | $-2.68 | $401,500 | 1 / 8 |
| 2026-07-26 | $-2.68 | $401,500 | 1 / 8 |
| 2026-07-27 | $-3.83 | $458,857 | 4 / 6 |
| 2026-07-28 | $-3.83 | $458,857 | 4 / 6 |
| 2026-07-29 | $-3.83 | $458,857 | 4 / 6 |
| 2026-07-30 | $-3.83 | $458,857 | 4 / 6 |
| 2026-07-31 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-01 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-02 | $-2.68 | $401,500 | 1 / 8 |
| 2026-08-03 | $-2.68 | $401,500 | 1 / 8 |
| 2026-08-04 | $-2.68 | $401,500 | 1 / 8 |
| 2026-08-05 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-06 | $-2.68 | $401,500 | 1 / 8 |
| 2026-08-08 | $-2.68 | $458,860 | 1 / 7 |
| 2026-08-09 | $-2.68 | $458,860 | 1 / 7 |
| 2026-08-10 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-12 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-13 | $-3.81 | $285,710 | 1 / 7 |
| 2026-08-14 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-15 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-16 | $-3.83 | $458,857 | 4 / 5 |
| 2026-08-17 | $-3.83 | $458,857 | 4 / 5 |
| 2026-08-18 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-19 | $-3.83 | $458,857 | 4 / 6 |
| 2026-08-20 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-21 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-22 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-23 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-24 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-25 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-26 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-27 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-28 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-29 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-30 | $-4.15 | $285,714 | 4 / 5 |
| 2026-08-31 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-01 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-02 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-03 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-04 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-05 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-06 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-07 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-08 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-09 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-10 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-11 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-12 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-13 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-14 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-15 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-16 | $-4.15 | $285,714 | 4 / 5 |
| 2026-09-17 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-18 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-19 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-20 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-21 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-22 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-23 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-24 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-25 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-26 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-27 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-28 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-29 | $-4.16 | $333,333 | 4 / 5 |
| 2026-09-30 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-01 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-02 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-03 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-04 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-05 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-06 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-07 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-08 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-09 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-10 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-11 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-12 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-13 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-14 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-15 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-16 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-17 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-18 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-19 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-20 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-21 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-22 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-23 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-24 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-25 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-26 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-27 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-28 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-29 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-30 | $-4.16 | $333,333 | 4 / 5 |
| 2026-10-31 | $-4.16 | $333,333 | 4 / 5 |
| 2026-11-01 | $-4.16 | $333,333 | 4 / 5 |
| 2026-11-02 | $-4.16 | $333,333 | 4 / 5 |
| 2026-11-03 | $-4.16 | $333,333 | 4 / 5 |
| 2026-11-04 | $-4.16 | $333,333 | 4 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.